|
PF-28393 |
3 TC 10 mg/mL solucion oral |
2007-08-22 |
|
Glaxo Group Ltd. |
Reino Unido
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-24699 |
VOLMAX 4 mg. Tabletas de liberacion prolongada |
2007-02-06 |
|
Glaxo Group Ltd. |
Reino Unido
|
Smithkline Beecham Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-28598 |
3TC 300 MG TABLETAS RECUBIERTAS |
2007-09-12 |
|
Glaxo Group Ltd. |
Reino Unido
|
Smithkline Beecham Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-18377 |
PYLORID 400 mg TABLETAS |
2007-05-06 |
|
Glaxo Group Ltd. |
Reino Unido
|
Smithkline Beecham Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-30996 |
LAMICTAL 50 mg comprimidos dispersables/masticables |
2013-07-21 |
|
Glaxo Wellcome Foundation Limited |
Reino Unido
|
Glaxosmithkline Guatemala S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59258 |
AUGMENTIN BID 200-28.5 mg/5mL Polvo para suspensión oral |
2026-04-07 |
|
Laboratoire GlaxoSmithKline |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59850 |
AUGMENTIN BID 400-57mg/5mL Polvo para suspensión oral |
2026-08-13 |
|
Glaxosmithkline |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-35475 |
RELENZA 5 mg Polvo para inhalación |
2025-02-18 |
|
Glaxosmithkline |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-39462 |
FASTURTEC 1.5 mg/mL polvo y solucion para uso parenteral |
2012-09-04 |
|
Sanofi Aventis |
Francia
|
Agefinsa (Agencia Farm. Intern., S.A.) |
Lanquetin S.A. |
Sanofi-Aventis de Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-43008 |
AUGMENTIN ES 600-42.9 mg/5mL Polvo para suspensión oral |
2028-08-22 |
|
GlaxoSmithkline Produtos Farmacéuticos, Lda. |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|